전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved29 programs
CGTLimited DatastaleEden BioCell Ltd.Phase 1

RPM CD19-mbIL15-CAR-T cells (RPM CD19-mbIL15-CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma, Relapsed · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
ADCLimited DatastaleTG Therapeutics, Inc.Phase 1

brentuximab vedotin (Adcetris, TGR-1202 + brentuximab vedotin)

Hodgkin's Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#ADC#Phase1#antibody-drug-conjugate#TG
Trials 1Status Active
CGTLimited DatastaleEdiGene Inc.Phase 2

TRAC and Power3 (SPPL3, TRAC and Power3, TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T))

Non Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleWellington Zhaotai Therapies Li…Phase 1

1928T2z CAR-T cells (WZTL002-1, WZTL002-1 (1928T2z CAR-T cells))

Lymphomas Non-Hodgkin's B-Cell; Diffuse Large B-cell Lymphoma (DLBCL) · Lymphomas Non-Hodgkin's B-Cell

#LymphomasNon-HodgkinsB-Cell#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#B-cellLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine and rituximab (fludarabine and rituximab)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine, rituximab, pixantrone (fludarabine, rituximab, pixantrone)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

RO5072759 (obinutuzumab, obinutuzumab (RO5072759))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#monoclonal-antibody#AdultNon-HodgkinsLymphoma+1
Trials 1Status Discontinued

2 / 2 pages

← PreviousNext →